GlassScriptPhysician profile
Zachary Field
NPI 1750879961
$6,859.58
in general payments reported to CMS, 2019-2025
31 companies · $2,328 in 2025
The $2,328 reported for 2025 was more than what 82% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $736 · 2022: $997 · 2023: $1,055 · 2024: $1,743 · 2025: $2,328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,962 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,961.99 |
| Education | $164.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,279.75 | 2021-2025 | |
| Janssen Biotech, INC. | $1,039.87 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $526.48 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $508.14 | 2021-2024 | Livdelzi, Epclusa |
| Celltrion USA INC. | $332.48 | 2024-2025 | Vegzelma, Zymfentra |
| Regeneron Healthcare Solutions, INC. | $298.47 | 2024-2025 | Dupixent |
| Madrigal Pharmaceuticals | $287.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $274.82 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $247.92 | 2024-2025 | |
| Janssen Scientific Affairs, LLC | $231.32 | 2021-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $221.89 | 2024-2025 | Sucraid, Sucraid |
| Conmed Corporation | $196.20 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.02 | 2021-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $155.81 | 2023-2025 | Omvoh, Zepbound |
| Medtronic, INC. | $149.90 | 2023 | Manoscan |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $125.00 | 2021 | |
| Apollo Endosurgery US INC | $118.95 | 2023 | Overstitch Endoscopic Suturing System |
| Erbe USA INC | $115.00 | 2023-2024 | Erbe Vio3, Erbe |
| Boston Scientific Corporation | $107.28 | 2024 | Exalt Model D |
| Merck Sharp & Dohme LLC | $100.45 | 2021-2024 | Dificid |
| Celgene Corporation | $64.13 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $59.65 | 2025 | Voquezna |
| Novo Nordisk INC | $50.38 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $49.98 | 2024-2025 | Zenpep |
| Enterra Medical, INC. | $42.67 | 2025 | |
| Intercept Pharmaceuticals, INC. | $31.99 | 2024-2025 | |
| Evoke Pharma, INC. | $21.87 | 2024 | |
| Braintree Laboratories, INC. | $20.56 | 2023 | Sutab, Suflave |
| Fresenius Kabi USA, LLC | $17.23 | 2024 | Idacio |
| Olympus America INC. | $14.88 | 2023 | Single Use Electrosurgical Knife Kd-655 |
| Pfizer INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zachary Field listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.